Relmada's Cancer Drug Candidate Sparks Fresh Bullish Call - Relmada Therapeutics (NASDAQ:RLMD)

HC Wainwright initiates Relmada Therapeutics (NASDAQ: RLMD) with a Buy rating and $12 target, highlighting its bladder cancer potential.

Raccontata dabenzinga.com